title: Therapeutic potential of thromboxane inhibitors in asthma.
abstract: This paper reviews the role of thromboxane A(2) (TXA(2)) in the pathogenesis of pulmonary allergies, particularly asthma. The potential of TXA(2) modifiers in the prevention and/or treatment of pulmonary allergies is also discussed. Bronchial asthma is characterised by reversible airway obstruction, bronchial hyperresponsiveness and inflammation. Several studies have elucidated the role of arachidonic acid metabolites (leukotrienes, prostaglandins and TXA(2)) in the pathogenesis of asthma. Among those mediators, TXA(2) has attracted attention due to its strong physiological activity. Indeed, TXA(2) demonstrates not only potent bronchoconstrictive activity but is also believed to be involved both in late asthmatic responses and in bronchial hyperresponsiveness, a typical feature of this disease. Several thromboxane receptor antagonists (TXRAs) and thromboxane synthase inhibitors (TXSIs) have been studied with the aim of reducing or preventing asthma. As double-blind, placebo-controlled clinical trials have proven the efficiency of some TXA(2) modifiers in treating asthma, the TP receptor antagonist seratrodast (AA-2414) and the thromboxane synthase inhibitor ozagrel hydrochloride (OKY-046) are now available as anti-asthmatic agents in Japan. Moreover, seratrodast and ramatroban (BAY-U-3405), another thromboxane receptor antagonist, are currently under Phase III clinical evaluation in the US for the treatment of asthma.
authors.affiliation: Department of Medicinal Chemistry, University of Liège, 1 avenue de l'Hôpital, B36, 4000 Liège, Belgium. Jean-Michel.Dogne@ulg.ac.be
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Dogné
authors.forename: Xavier
authors.initials: X
authors.lastname: de Leval
authors.forename: Patricia
authors.initials: P
authors.lastname: Benoit
authors.forename: Stephanie
authors.initials: S
authors.lastname: Rolin
authors.forename: Bernard
authors.initials: B
authors.lastname: Pirotte
authors.forename: Bernard
authors.initials: B
authors.lastname: Masereel
mesh_terms: D001249:Asthma / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D015289:Leukotrienes / Q000378:metabolism; D011453:Prostaglandins / Q000378:metabolism; D017482:Receptors, Thromboxane / Q000037:antagonists & inhibitors; D013928:Thromboxane A2 / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D015289:Leukotrienes; D011453:Prostaglandins; D017482:Receptors, Thromboxane; D013928:Thromboxane A2